News and Trends 2 Sep 2024
Are we in an AI bubble? Biotech AI startups’ value plummet and leads to restructuration
Delve into the downturn AI is experiencing in biotech: Is the bubble bursting or is the market correcting the high expectations?
Partnerships
- Latest Posts
Best in Biotech 2 Aug 2024
Six epigenetics companies making strides in 2024
In this article, we take a look at six epigenetics companies that are significant as well as up-and-coming players in the industry.
In Depth 1 Aug 2024
CureVac: From a failed drug to a €1.45 billion deal
In 2021, CureVac’s COVID-19 candidate came short. Discover how the company leveraged its deal with GSK to restructure and turn things around.
In Depth 30 Jul 2024
Why is the immunology and inflammation market suddenly attracting a wave of investment?
Discover why the immunology and inflammation market has recently been attracting a major wave of investment.
More News! 23 Jul 2024
First AKT-targeting drug capivasertib to hit the market, could it open the door for more?
As AstraZeneca and Astex’s capivasertib gains market presence in breast cancer, could it be the time for AKT inhibitors? Let’s find out!
Expert Advice 19 Jul 2024
The ABC of biotech partnerships
Discover eight different types of biotech partnerships, including what each one entails and its advantages and disadvantages.
ADVERTISEMENT
ADVERTISEMENT
Best in Biotech 11 Jul 2024
From data to discovery: Five bioinformatics companies you should know in 2024
Bioinformatics integrates computer technology to analyze biological data to boost R&D. Here are five companies at the top of their game in 2024.
Best in Biotech 9 Jul 2024
The 7 biotech companies in Portugal you should know about in 2024
We take a look at seven biotech companies in Portugal, which is home to a rich biotech ecosystem that is rapidly growing.
Expert Advice 5 Jul 2024
The ABC of biotech startup funding
Funding a biotech startup can be challenging. Delve into our guide to navigate this complicated investment landscape.
In Depth 26 Jun 2024
Biotech megadeals: Exploring the surge in $100M+ deals
Biotech and healtcare contributed to more than one out of three megadeals in 2024, find out the reasons behind it.
In Depth 24 Jun 2024
Troublesome acquisitions: when biotech M&A goes wrong
Dive deeper into the world of M&A, as we take a look at some of the most prominent failed acquisitions of the last decade.
Best in Biotech 20 Jun 2024
CRISPR technology’s next wave: Eight companies to watch in 2024
Driven by CASGEVY’s success, the CRISPR field is experiencing substantial growth with a new wave of companies.
ADVERTISEMENT
